While traditional imaging methods like FDG-PET are effective for detecting highly metabolic cancer cells, they fall short in specifically imaging the tumor microenvironment. Fibroblast Activation Protein (FAP)-targeted PET imaging addresses this by specifically visualizing the tumor stroma, which is richly populated with cancer-associated fibroblasts. This targeted approach introduces a new dimension in tumor evaluation, with applicability across a wide range of cancers.
Moreover, the high expression of FAP in fibrotic diseases further highlights its broad utility as a biomarker across diverse pathological conditions. FAP inhibitors (FAPI) enable non-invasive imaging of FAP, providing enhanced diagnostic precision while unlocking theranostic potential in both oncology and fibrotic disease applications.
Moderator: Paulo Rosado de Castro MD, PhD
Medical Director at Perceptive
Co-founder, President, and CSO, Ratio Therapeutics
Associate Professor, Department of Molecular and Medical Pharmacology; Director, Theranostics Program, David Geffen School of Medicine at UCLA
Professor of Nuclear Medicine, Universitätsmedizin Essen, Universität Duisburg-Essen, Germany
Chief Scientific Officer, SOFIE
Complete the form below to access the recording.
"*" indicates required fields
Δ
